Benzinga | Nov 3, 2021 04:01PM EDT

Cytokinetics Q3 EPS $(0.95) Misses $(0.76) Estimate, Sales $5.40M Miss $6.42M Estimate

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.76) by 25 percent. This is a 1800 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $5.40 million which missed the analyst consensus estimate of $6.42 million by 15.89 percent. This is a 87.05 percent decrease over sales of $41.69 million the same period last year.